Chan ACY, Wilder-Smith EP. Small fiber neuropathy: getting bigger! Muscle Nerve. 2016;53:671–82.
Gibbons CH. Small fiber neuropathies. Continuum. 2014;20:1398–412.
Shun CT, Chang YC, Wu HP, et al. Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairments. Brain. 2004;127:1593–605.
Boruchow SA, Gibbons CH. Utility of skin biopsy in management of small fiber neuropathy. Muscle Nerve. 2013;48:877–82.
Khoshnoodi MA, Truelove S, Burakgazi A, et al. Longitudinal assessment of small fiber neuropathy: evidence of a non-length-dependent distal axonopathy. JAMA Neurol. 2016;73:684–90.
Chao CC, Wu VC, Tan CH, et al. Skin denervation and its clinical significance in late-stage chronic kidney disease. Arch Neurol. 2011;68:200–6.
Singleton JR, Marcus RL, Lessard MK, et al. Supervised exercise improves cutaneous reinnervation capacity in metabolic syndrome patients. Ann Neurol. 2015;77:146–53.
Fokke C, van den Berg B, Drenthen J, et al. Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria. Brain. 2014;137:33–43.
Oaklander AL, Lunn MP, Hughes RA, et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017. https://doi.org/10.1002/14651858.CD010369.pub2.
Pan CL, Tseng TJ, Lin YH, et al. Cutaneous innervation in Guillain-Barre syndrome: pathology and clinical correlations. Brain. 2003;126:386–97.
Martinez V, Fletcher D, Martin F, et al. Small fibre impairment predicts neuropathic pain in Guillain-Barre syndrome. Pain. 2010;151:53–60.
Binder A, Baron R. Size matters—small fiber neuropathy in the Guillain-Barre syndrome. Pain. 2010;151:9–10.
Ruts L, van Doorn PA, Lombardi R, et al. Unmyelinated and myelinated skin nerve damage in Guillain-Barre syndrome: correlation with pain and recovery. Pain. 2012;153:399–409.
Chao CC, Hsieh ST, Chiu MJ, et al. Effects of aging on contact heat evoked potentials: the physiological assessment of thermal perception. Muscle Nerve. 2007;36:30–8.
Atherton D, Facer P, Roberts K, et al. Use of the novel contact heat evoked potential stimulator (CHEPS) for the assessment of small fibre neuropathy: correlations with skin flare responses and intra-epidermal nerve fibre counts. BMC Neurol. 2007;7:21.
Granovsky Y, Granot M, Nir RR, et al. Objective correlate of subjective pain perception by contact heat-evoked potentials. J Pain. 2008;9:53–63.
Lagerburg V, Bakkers M, Bouwhuis A, et al. Contact heat evoked potentials: normal values and use in small-fiber neuropathy. Muscle Nerve. 2015;51:743–9.
Parson HK, Nguyen VT, Orciga MA, et al. Contact heat-evoked potential stimulation for the evaluation of small nerve fiber function. Diabetes Technol Ther. 2013;15:150–7.
Zhang C, Xie B, Li X, et al. Contact heat-evoked potentials as a useful means in patients with Guillain-Barre syndrome. Neurol Sci. 2014;35:1209–14.
Tseng MT, Chiang MC, Chao CC, et al. fMRI evidence of degeneration-induced neuropathic pain in diabetes: enhanced limbic and striatal activations. Hum Brain Mapp. 2013;34:2733–46.
Tesfaye S, Selvarajah D, Gandhi R, et al. Diabetic peripheral neuropathy may not be as its name suggests: evidence from magnetic resonance imaging. Pain. 2016;157(Suppl 1):S72–80.
Segerdahl AR, Themistocleous AC, Fido D, et al. A brain-based pain facilitation mechanism contributes to painful diabetic polyneuropathy. Brain. 2018;141:357–64.
Uncini A, Yuki N. Sensory Guillain-Barre syndrome and related disorders: an attempt at systematization. Muscle Nerve. 2012;45:464–70.
Koike H, Atsuta N, Adachi H, et al. Clinicopathological features of acute autonomic and sensory neuropathy. Brain. 2010;133:2881–96.
Pfund Z, Stankovics J, Decsi T, et al. Childhood steroid-responsive acute erythromelalgia with axonal neuropathy of large myelinated fibers: a dysimmune neuropathy? Neuromuscul Disord. 2009;19:49–52.
Paticoff J, Valovska A, Nedeljkovic SS, et al. Defining a treatable cause of erythromelalgia: acute adolescent autoimmune small-fiber axonopathy. Anesth Analg. 2007;104:438–41.
Makonahalli R, Seneviratne J, Seneviratne U. Acute small fiber neuropathy following mycoplasma infection: a rare variant of Guillain-Barre syndrome. J Clin Neuromuscul Dis. 2014;15(4):147–51.
Yuki N, Chan AC, Wong AHY, et al. Acute painful autoimmune neuropathy: a variant of Guillain-Barre syndrome. Muscle Nerve. 2018;57:320–4.
Pan CL, Yuki N, Koga M, et al. Acute sensory ataxic neuropathy associated with monospecific anti-GD1b IgG antibody. Neurology. 2001;57:1316–8.
Chiang MC, Lin YH, Pan CL, et al. Cutaneous innervation in chronic inflammatory demyelinating polyneuropathy. Neurology. 2002;59:1094–8.
Figueroa JJ, Dyck PJB, Laughlin RS, et al. Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2012;78:702–8.
Mauermann ML, Sorenson EJ, Dispenzieri A, et al. Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP. J Neurol Neurosurg Psychiatry. 2012;83:480–6.
Vital C, Gherardi R, Vital A, et al. Uncompacted myelin lamellae in polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes syndrome. Acta Neuropathol. 1994;87:302–7.
Piccione EA, Engelstad J, Dyck PJ, et al. Nerve pathologic features differentiate POEMS syndrome from CIDP. Acta Neuropathol Commun. 2016;4:116.
Ohyama K, Koike H, Hashimoto R, et al. Intraepidermal nerve fibre density in POEMS (Crow-Fukase) syndrome and the correlation with sural nerve pathology. J Neurol Sci. 2016;365:207–11.
Koike H, Iijima M, Mori K, et al. Neuropathic pain correlates with myelinated fibre loss and cytokine profile in POEMS syndrome. J Neurol Neurosurg Psychiatry. 2008;79:1171.
Scarlato M, Previtali SC, Carpo M, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain. 2005;128:1911–20.
McCrary J, Goldstein D, Boyle F, et al. Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Support Care Cancer. 2017;25:3485–93.
Curcio KR. Instruments for assessing chemotherapy-induced peripheral neuropathy: a review of the literature. Clin J Oncol Nurs. 2016;20:144–51.
Winters-Stone KM, Horak F, Jacobs PG, et al. Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2017;35:2604–12.
Zirpoli GR, McCann SE, Sucheston-Campbell LE, et al. Supplement use and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221): the DELCaP study. J Natl Cancer Inst. 2017;109(12). https://doi.org/10.1093/jnci/djx098.
Miaskowski C, Mastick J, Paul SM, et al. Chemotherapy-induced neuropathy in cancer survivors. J Pain Symptom Manag. 2017;54:204–18.
Park SB, Kwok JB, Asher R, et al. Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol. 2017;28:2733–40.
Pachman DR, Qin R, Seisler D, et al. Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer. 2016;24:5059–68.
Koskinen MJ, Kautio AL, Haanpaa ML, et al. Intraepidermal nerve fibre density in cancer patients receiving adjuvant chemotherapy. Anticancer Res. 2011;31:4413–6.
Kroigard T, Schroder HD, Qvortrup C, et al. Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies. Eur J Neurol. 2014;21:623–9.
Velasco R, Navarro X, Gil-Gil M, et al. Neuropathic pain and nerve growth factor in chemotherapy-induced peripheral neuropathy: prospective clinical-pathological study. J Pain Symptom Manag. 2017;54:815–25.
Ventzel L, Madsen CS, Karlsson P, et al. Chronic pain and neuropathy following adjuvant chemotherapy. Pain Med. 2018;19(9):1813–24.
Saad M, Psimaras D, Tafani C, et al. Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy. J Neuro-Oncol. 2016;127:373–80.
Sharma S, Venkitaraman R, Vas PRJ, et al. Assessment of chemotherapy-induced peripheral neuropathy using the LDI (FLARE) technique: a novel technique to detect neural small fiber dysfunction. Brain Behav. 2015;5:e00354.
Lieber S, Blankenburg M, Apel K, et al. Small-fiber neuropathy and pain sensitization in survivors of pediatric acute lymphoblastic leukemia. Eur J Paediatr Neurol. 2018;22(3):457–69.
Kokotis P, Schmelz M, Kostouros E, et al. Oxaliplatin-induced neuropathy: a long-term clinical and neurophysiologic follow-up study. Clin Colorectal Cancer. 2016;15:e133–40.
Boyette-Davis JA, Cata JP, Driver LC, et al. Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine. Cancer Chemother Pharmacol. 2013;71:619–26.
Dermitzakis EV, Kimiskidis VK, Lazaridis G, et al. The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer. BMC Neurol. 2016;16:190.
Weis J, Claeys KG, Roos A, et al. Towards a functional pathology of hereditary neuropathies. Acta Neuropathol. 2017;133:493–515.
Fledrich R, Mannil M, Leha A, et al. Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A. J Neurol Neurosurg Psychiatry. 2017;88:941–52.
Pisciotta C, Shy ME. Neuropathy. In: Geschwind DH, Paulson HL, Klein C, editors. Handbook of clinical neurology (Neurogenetics, Part II) 2018;148. p. 653–65.
Jerath NU, Shy ME. Hereditary motor and sensory neuropathies: understanding molecular pathogenesis could lead to future treatment strategies. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2015;1852:667–78.
Li J, Bai Y, Ghandour K, et al. Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain. 2005;128:1168–77.
Manganelli F, Nolano M, Pisciotta C, et al. Charcot-Marie-Tooth disease: new insights from skin biopsy. Neurology. 2015;85:1202–8.
Katona I, Wu X, Feely SME, et al. PMP22 expression in dermal nerve myelin from patients with CMT1A. Brain. 2009;132:1734–40.
Nobbio L, on behalf of the CMT-TRIAAL Group, Visigalli D, et al. PMP22 messenger RNA levels in skin biopsies: testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker. Brain. 2014;137:1614–20.
Soldevilla B, Cuevas-Martin C, Ibanez C, et al. Plasma metabolome and skin proteins in Charcot-Marie-Tooth 1A patients. PLoS One. 2017;12:e0178376.
Tavakoli M, Marshall A, Banka S, et al. Corneal confocal microscopy detects small fiber neuropathy in CMT1A patients. Muscle Nerve. 2012;46:698–704.
Duchesne M, Danigo A, Richard L, et al. Skin biopsy findings in patients with CMT1A: baseline data from the CLN-PXT3003-01 study provide new insights into the pathophysiology of the disorder. J Neuropathol Exp Neurol. 2018;77:274–81.
Nolano M, Manganelli F, Provitera V, et al. Small nerve fiber involvement in CMT1A. Neurology. 2015;84:407–14.
Casanova-Molla J, Morales M, Planas-Rigol E, et al. Epidermal Langerhans cells in small fiber neuropathies. Pain. 2012;153:982–9.
Hsieh ST, Choi S, Lin WM, et al. Epidermal denervation and its effects on keratinocytes and Langerhans cells. J Neurocytol. 1996;25:513–24.
Strom A, Bruggemann J, Ziegler I, et al. Pronounced reduction of cutaneous Langerhans cell density in recently diagnosed type 2 diabetes. Diabetes. 2014;63:1148–53.
Uceyler N, Devigili G, Toyka K, et al. Skin biopsy as an additional diagnostic tool in non-systemic vasculitic neuropathy. Acta Neuropathol. 2010;120:109–16.
Tseng MT, Hsieh SC, Shun CT, et al. Skin denervation and cutaneous vasculitis in systemic lupus erythematosus. Brain. 2006;129:977–85.
Chao CC, Hsieh ST, Shun CT, et al. Skin denervation and cutaneous vasculitis in eosinophilia-associated neuropathy. Arch Neurol. 2007;64:959–65.
Yang NC, Lee MJ, Chao CC, et al. Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser. Neurology. 2010;75:532–8.
Chao CC, Huang CM, Chiang HH, et al. Sudomotor innervation in transthyretin amyloid neuropathy: pathology and functional correlates. Ann Neurol. 2015;78:272–83.
Suenaga G, Ikeda T, Masuda T, et al. Inflammatory state exists in familial amyloid polyneuropathy that may be triggered by mutated transthyretin. Sci Rep. 2017;7:1579.
Martins D, Moreira J, Goncalves NP, et al. MMP-14 overexpression correlates with the neurodegenerative process in familial amyloidotic polyneuropathy. Dis Model Mech. 2017;10:1253–60.
Waldfogel JM, Nesbit SA, Dy SM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life. Neurology. 2017;88:1958–67.
Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785–92.
Bakkers M, Faber CG, Hoeijmakers Janneke GJ, et al. Small fibers, large impact: quality of life in small fiber neuropathy. Muscle Nerve. 2013;49:329–36.
Lin MT, Lee LJH, Chao CC, et al. Quality of life in polyneuropathy: association with biomarkers of small fiber impairment. Health Qual Life Outcomes. 2015;13:169.